Discovery of a novel potent GABA(B) receptor agonist

Structure-activity studies have led to a discovery of 3-(4-pyridyl)methyl ether derivative 9d that has 25- to 50-fold greater functional potency than R-baclofen at human and rodent GABA(B) receptors in vitro. Mouse hypothermia studies confirm that this compound crosses the blood-brain barrier and is approximately 50-fold more potent after systemic administration.     

Baclofen and NOS inhibitors interact to evoke synergistic hypothermia in rats

Our laboratory recently demonstrated that a drug combination of baclofen and L-NAME, a nonspecific nitric oxide synthase (NOS) inhibitor, evokes synergistic hypothermia in rats. These data are the first demonstration of synergy between a GABA agonist and NOS inhibitor. While the hypothermic synergy suggests a role for NOS in baclofen pharmacology, it is unclear whether the super-additive hypothermia is specific for baclofen and L-NAME or extends to drug combinations of baclofen and other NOS inhibitors. The site of action (central or peripheral) and isoforms of NOS that mediate the synergy are also unknown. Here, we confirm the hypothermic synergy with additional data and discuss potential mechanisms of the drug interaction. Baclofen (2.5, 3.5, 5 and 7.5 mg/kg, i.p.) was administered to rats by itself or with 7-nitroindazole (7-NI), a neuronal NOS inhibitor. 7-NI (10 mg/kg, i.p.) did not affect body temperature. For combined administration, 7-NI (10 mg/kg, i.p.) increased the relative potency of baclofen (F=18.9, P<0.05). The present data validate the hypothermic synergy caused by the drug combination of baclofen and L-NAME and implicate nNOS in the synergy. In a context broader than thermoregulation, NO production and transmission may play an important role in baclofen pharmacology.     

Age and monosodium glutamate treatment cause changes in the stimulation-induced [3H]-norepinephrine release from rat nucleus tractus solitarii-dorsal vagal nucleus slices

In nucleus tractus solitarii-dorsal vagal nucleus slices prepared from young adult rats (180-260 g) 10(-3) M L-glutamate and 10(-5) M baclofen caused a 2-3-fold increase of field stimulation-induced [3H]-norepinephrine release without affecting the resting release. In slices prepared from rats treated neonatally with monosodium glutamate neither L-glutamate nor baclofen had any effect on stimulation-induced norepinephrine release, tested between postnatal days 74-99 (350-530 g). In untreated littermates used in the same period (460-580 g) L-glutamate was fully effective whereas baclofen was ineffective. The tritium content in tissue extracts did not differ significantly in the three experimental groups. It is concluded that i) the loss of GABA(B) receptor-mediated disinhibitory stimulation of norepinephrine release is an age-related phenomenon and ii) neonatal monosodium glutamate treatment causes a damage in the local neural circuitry characterized by the loss of glutamate receptor-mediated mechanism that stimulates the release of norepinephrine.     

Characteristics of the Large Neutral Amino Acid Transport System of Bovine Brain Microvessel Endothelial Cell Monolayers

The large neutral amino acid (LNAA) transport system, or L (leucine) system, in primary cultures of bovine brain microvessel endothelial cell monolayers has been characterized. The transendothelial transport of leucine in this in vitro blood-brain barrier (BBB) model was determined to be bidirectional and time, temperature, and concentration dependent. Leucine transport was saturable, and the apparent Km and Vmax were determined to be 0.18 mM and 6.3 nmol/mg/min, respectively. Transendothelial transport of leucine was resistant to inhibition by ouabain and sodium azide. Other LNAAs, including the centrally acting drugs alpha-methyl-3,4-dihydroxyphenylalanine (alpha-methyldopa), L-3,4-dihydroxyphenylalanine (L-DOPA), alpha-methyltyrosine, and baclofen, inhibited leucine transport. The leucine carrier system was also found to be stereospecific. Sucrose, used as a diffusion marker, moved across the monolayers slowly, and its concentration was not significant for at least 30 min.     

Accumulation of Cyclic AMP Elicited by Vasoactive Intestinal Peptide Is Potentiated by Noradrenaline, Histamine, Adenosine, Baclofen, Phorbol Esters, and Ouabain in Mouse Cerebral Cortical Slices: Studies on the Role of Arachidonic Acid Metabolites and Protein Kinase C

In mouse cerebral cortical slices, noradrenaline (NA) potentiates cyclic AMP (cAMP) accumulation elicited by vasoactive intestinal peptide (VIP) through alpha 1-adrenergic receptors. This synergism is inhibited by indomethacin, and the prostaglandins E2 and F2 alpha mimic the effect of NA. In the present study, we observed that the synergism between VIP and NA is not inhibited by the protein kinase C inhibitor 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7) or the diacylglycerol-lipase inhibitor RHC 80267, thus further stressing the role of phospholipase A2 activation. Various neuroactive agents that potentiate the stimulatory effect of VIP on cAMP formation were also examined. As with NA, the potentiation by histamine and adenosine is inhibited by indomethacin. In contrast to NA, histamine, and adenosine, the synergistic interaction between phorbol esters and VIP on cAMP formation is abolished by H-7 but not by indomethacin. The potentiation by baclofen, a gamma-aminobutyric acidB receptor agonist, is partially inhibited by the 5-lipoxygenase inhibitor nafazatrom. The synergism between ouabain and VIP is reduced by H-7 but not by indomethacin and nafazatrom. These data indicate that the stimulation of cAMP formation elicited by VIP is under the modulation of various neuroactive agents that trigger diverse intracellular mechanisms to potentiate the effect of the peptide.     

Distribution of γ-aminobutyric acid in catfish (Heteropneustes fossilis) forebrain in relation to season, ovariectomy and E2 replacement, and effects of GABA administration on plasma Gonadotropin-II level

In the catfish Heteropneustes fossilis, the hypothalamus and telencephalon showed seasonal variations in γ-aminobutyric acid (GABA) with high levels in prespawning and spawning phases and low levels in preparatory and postspawning phases. Ovariectomy for 4 and 5 weeks reduced significantly the GABA contents only in the hypothalamus. Replacement with E₂ (1 μg/g BW) restored the levels to that of sham ovariectomized or parallel control group. Treatment with GABA (i.p.; 10 or 50 μg/g body weight (BW)) alone did not produce any significant effect on plasma gonadotropin-II (GTH-II) level in any of the seasons. Injection of GABA, but not baclofen (a GABA_B agonist), stimulated GTH-II secretion in pimozide or GnRH analogue-pimozide pretreated fish at both 0.5 and 2 h in early prespawning phase except at 0.5 h in the pimozide—GABA (10 μg) group. This stimulatory effect was not evident in other seasons. The results of the present study suggest that Estradiol-17β (E₂) seems to stimulate GABA which may account for its high level in the recrudescent phase. GABA seems to have a permissive role in GTH-II secretion when dopamine receptor function is inhibited.     

Effects of Dihydropyridine Calcium Channel Ligands on Rat Brain γ-Aminobutyric AcidB Receptors

This study shows that low nanomolar concentrations of the calcium channel antagonist nifedipine displaced [3H]baclofen labeling of gamma-aminobutyric acidB (GABAB) receptors, whereas similar concentrations of two calcium channel agonists stimulated this GABAB receptor labeling. Neither effect was likely to be due to dihydropyridine (DHP) binding to baclofen recognition sites, because the inhibitory ligand nifedipine primarily affected apparent receptor density rather than affinity. Although these results could reflect the coupling of GABAB receptors with calcium channels, they do not rule out other, possibly more direct interactions between GABAB receptors and DHP binding sites. These DHP effects occur at much lower concentrations and display other significant differences from previously reported effects of DHPs on other transmitter receptors.     

Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation

This work aims at investigating different types and levels of hydrophilic matrixing agents, including methylcellulose (MC), sodium alginate (Alg), and sodium carboxymethylcellulose (CMC), in an attempt to formulate controlled-release matrix tablets containing 25 mg baclofen. The tablets were prepared by wet granulation. Prior to compression, the prepared granules were evaluated for flow and compression characteristics. In vitro, newly formulated controlled-release tablets were compared with standard commercial tablets (Lioresal and baclofen). The excipients used in this study did not alter physicochemical properties of the drug, as tested by the thermal analysis using differential scanning calorimetry. The flow and compression characteristics of the prepared granules significantly improved by virtue of granulation process. Also, the prepared matrix tablets showed good mechanical properties (hardness and friability). MC- and Alg-based tablet formulations showed high release-retarding efficiency, and good reproducibility and stability of the drug release profiles when stored for 6 months in ambient room conditions, suggesting that MC and Alg are good candidates for preparing modified-release baclofen tablet formulations.     

Bicuculline- and Baclofen-Insensitive γ-Aminobutyric Acid Binding to Rat Cerebellar Membranes

Up to 60% of gamma-[3H]aminobutyric acid ([3H]GABA) bound specifically to rat cerebellar membranes in the absence of Ca2+ was insensitive to the GABAA antagonist bicuculline and to the GABAB agonist baclofen. This indicates that a significant component of specifically bound [3H]GABA is associated with non-GABAA, non-GABAB binding sites. The presence of this binding component appeared seasonal, peaking in the month of September (early spring) each year over a 4-year period. The calcium independence and bicuculline and baclofen insensitivity of the binding indicate that this binding is not to the classical GABAA and GABAB binding sites. High concentrations of muscimol and isoguvacine inhibited non-GABAA, non-GABAB binding. Scatchard analysis of the non-GABAA, non-GABAB binding sites indicated two kinetic components: KD1 = 42 nM and KD2 = 9.2 microM; Bmax1 = 1.6 pmol/mg of protein and Bmax2 = 28 pmol/mg of protein.     

GABA对小鼠大脑皮质中GABA受体胚胎发育的调节

本文用ＧＡＢＡ及其受体激动剂和拮抗剂处理培养的胚胎小鼠大脑皮层神经细胞以及精确计时的妊娠小鼠,用放射配体结合法检测ＧＡＢＡＡ及ＧＡＢＡＢ的结合位点数目,研究了ＧＡＢＡ对小鼠大脑皮层ＧＡＢＡ受体胚胎发育的调节作用,结果表明：①ＧＡＢＡ可使培养１５—１７天妊龄的胚胎小鼠大脑皮层神经细胞及出生第１天的仔鼠大脑皮层中的ＧＡＢＡＡ及ＧＡＢＡＢ受体数目增加,这种作用可被蝇蕈醇（Ｍｕｓ）及巴氯芬（Ｂａｃ）分别模拟,对ＧＡＢＡＡ受体的作用可为荷包牡丹碱（Ｂｉｃ）所阻断;②用ＧＡＢＡ处理妊娠７—１３天的小鼠,仔鼠出生第１天其大脑皮层的ＧＡＢＡＡ及ＧＡＢＡＢ受体数目均无变化;③用ＧＡＢＡ处理妊娠１４—１９天的小鼠,仔鼠出生的第１天其大脑皮层中的ＧＡＢＡＡ受体数目增加而ＧＡＢＡＢ受体数目不变;④用ＧＡＢＡ处理妊娠７－１９天的小鼠,仔鼠出生第１天其大脑皮层中ＧＡＢＡＡ及ＧＡＢＡＢ受体数目增加。这说明在胚胎发育的特定时期内,ＧＡＢＡ可诱导其受体数目的增加,这个作用是由ＧＡＢＡ受体调节的。